Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62,162,717
-
Total 13F shares
-
56,712,373
-
Share change
-
+73,783
-
Total reported value
-
$945,896,121
-
Put/Call ratio
-
11%
-
Price per share
-
$16.68
-
Number of holders
-
142
-
Value change
-
-$53,252,231
-
Number of buys
-
82
-
Number of sells
-
75
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2023
As of 30 Sep 2023 Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) had 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 56,712,373 shares of stock of the company.
Largest 10 holders included BVF INC/IL, FARALLON CAPITAL MANAGEMENT LLC, RTW INVESTMENTS, LP, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, JOHNSON & JOHNSON, Kynam Capital Management, LP, COWEN AND COMPANY, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 142 institutional shareholders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.